Cabaletta Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

2018 Stock Option and Grant Plan (Tables)

2018 Stock Option and Grant Plan (Tables)

9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

A summary of the stock option activity under the 2018 Plan is presented below:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding as of January 1, 2019		971,353		$	1.01		—	$	—
Granted		988,058			7.11
Forfeited		(17,000	)		1.01
Outstanding as of September 30, 2019		1,942,411			4.11		9.2		10,547
Options Exercisable at September 30, 2019		108,378			2.36		6.2		778

Summary of Stock-Based Compensation

The Company recognizes stock-based compensation with respect to equity awards under the 2018 Plan and with respect to vesting common stock issued to founders. The Company has recorded stock-based compensation in the accompanying statements of operations as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and development	$	365	$	151	$	962	$	252
General and administrative		204		44		519		74
Total	$	569	$	195	$	1,481	$	326